Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP
Amandeep Salhotra, MD
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP
Hana Safah, MD
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.